Today, the World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL). The test detects the virus by identifying its genetic material in blood samples, helping confirm infection rapidly and accurately.WHO’s EUL procedure assesses the quality, safety and performance of essential health products based on the available evidence, while ensuring they meet minimum international standards and address the needs of low- and middle-income countries.Through this mechanism, WHO aims to accelerate access to reliable diagnostic tools for early case detection, timely clinical care, disease surveillance and effective outbreak response. The EUL also supports United Nations procurement agencies and governments in making informed decisions about the procurement and use of these products in public health emergency settings."Public health emergencies require not only speed, but also confidence that the health products being used meet standards for quality, safety and performance," said Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data. "During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission. Through this Emergency Use Listing, WHO is helping countries access trusted diagnostic tools more rapidly so that they can respond more effectively.”On 17 May 2026, WHO Director-General Dr Tedros Adhanom Ghebreyesus declared a public health emergency of international concern over the outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo, with cases in Uganda. Less than two weeks later, WHO launched a call for manufacturers of IVDs for Bundibugyo virus to submit Expressions of Interest for Emergency Use Listing.The listing comes at a critical time as countries respond to the largest recorded outbreak of Ebola disease caused by BDBV, which continues to expand. As of today, 1406 laboratory-confirmed cases and 438 deaths had been reported in the Democratic Republic of the Congo alone.With support from WHO and the Africa Centres for Disease Control and Prevention (Africa CDC), laboratory testing capacity has expanded from a limited number of sites – primarily Institut National de Recherche Biomédicale in Kinshasa and Goma, with an estimated combined capacity of approximately 200–400 tests per day – to a broader network of 10 laboratories across affected provinces, with a reported capacity of over 2000 tests per day. Rapid and reliable diagnosis remains essential to identify cases early, guide timely patient care, interruptand help bring outbreaks under control.WHO continues to work closely with manufacturers, global partners and countries to expand the availability of and access to safe, effective and quality-assured life-saving health products. Additional applications for BDBV IVDs submitted through the EUL procedure are currently under review.In parallel, WHO and Africa CDC, with partners including PATH, FIND and CHAI, and with support from Unitaid, are establishing a joint validation platform to rapidly evaluate the performance of a selection of diagnostic products, including laboratory-based molecular tests, near-point-of-care molecular tests and antigen rapid diagnostic tests. The platform will generate critically needed clinical evidence on the performance of these products in outbreak settings.Bundibugyo virus disease is a severe, often life-threatening disease caused by BDBV, one of three Ebola virus species known to cause large outbreaks in humans. The virus can spread from animals to humans and then from person to person through contact with a person sick or deceased and their infected bodily fluids or surfaces or items contaminated by these fluids.Information on active EUL applications for IVDs for BDBV nucleic acid detection can be found on these WHO webpages.About WHODedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life.We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to support countries to promote, provide and protect health.“Together for health. Stand with science”, the theme of World Health Day 2026 marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide. 

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.

At a time when energy security and affordability have risen to the top of the development agenda, 655 million people globally still lack access to electricity, and two billion use polluting fuels and technologies for cooking putting their health and well-being at risk.

The World Health Organization (WHO) today calls on countries to expand newborn screening for birth defects, highlighting how early detection and treatment can save lives and reduce lifelong disability for millions of children.A new WHO report, Strengthening capacity for newborn screening, diagnosis and management of birth defects, identifies newborn screening as an important opportunity to accelerate progress in child survival.Many conditions can be successfully treated if identified early after birth. These include congenital hypothyroidism, sickle-cell disease, hearing impairment and some metabolic disorders. Yet millions of children are still diagnosed too late or never receive treatment at all.Worldwide, an estimated 8 million babies are born with a birth defect each year, and birth defects now account for almost 8% of all deaths among children under five. An estimated 90% of children born with serious birth defects live in low- and middle-income countries, where access to screening, diagnosis and treatment remains limited."No child should miss the chance for a healthy future because a congenital condition was not detected early enough," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Around the world, countries are showing that newborn screening for one or more conditions can save lives, prevent disability, and give a newborn the best opportunity to fulfil her or his potential ."The gap between countries is stark: some countries screen all newborns for more than 50 conditions, while others are unable to screen for any. WHO encourages every country to begin newborn screening — starting with a priority condition in the country and progressively expanding as capacity grows.The report shows that birth defects account for a growing proportion of under-five deaths in many regions. Between 2000 and 2023, the proportion of under-five deaths attributable to birth defects increased from 1% to 4% in sub-Saharan Africa and from 3% to 11% in South Asia. Part of this shift reflects genuine progress in the reduction of deaths from infectious and other preventable causes.The WHO report aims to support ministries of health, especially in low- and middle-income countries, to prioritize conditions for newborn screening depending on the country context.It showcases countries across Africa, Asia and the Americas that are already demonstrating the successful integration of large-scale newborn screening programmes into routine health services:Argentina: Increased newborn screening coverage to nearly universal levels.Brazil: Expanded nationwide screening for multiple life-threatening conditions.Egypt:  The ‘newborn care pathway’ integrates universal newborn screening for hearing and congenital hypothyroidism into its primary health care services.India: The national programme has screened more than 28 million children over three years, identifying approximately 900,000 children with a birth defect and connecting them with diagnosis, treatment and support, including long term care and rehabilitation services through district early intervention centres.Philippines: A programme that began as a pilot in 24 hospitals now screens newborns for 29 conditions through more than 7000 facilities nationwide. All conditions screened for have diagnostic and management pathways within the national health system. Newborn screening is covered by national health insurance and mandated by law.Sri Lanka: Newborn screening is integrated into routine care and includes visible birth defects and congenital hypothyroidism. Around 80% of newborns are now screened for congenital hypothyroidism.Uganda: A state-led programme for sickle-cell disease in high burden areas identifies affected infants early and provides them with lifesaving treatment and long-term follow-up care.WHO is urging governments to integrate newborn screening, diagnosis and treatment into routine health services and universal health coverage programmes, beginning with conditions that are country priorities, and that can be effectively detected and feasibly managed within their health system.The report was informed by a global WHO consultation bringing together government representatives, technical experts, clinicians, researchers, professional associations, civil society organizations and families affected by birth defects to identify priorities for strengthening newborn screening, diagnosis and long-term care.About WHODedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the United Nations’ agency for health that connects nations, partners and people in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to support all countries to promote, provide and protect health.“Together for health. Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide. 

As the Democratic Republic of the Congo is battling an Ebola disease outbreak caused by the Bundibugyo virus, the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus disease which include all types of Ebola and Marburg viruses. The new guidelines highlight the importance of early supportive care to improve patient survival and health outcomes, outlining 16 evidence-based recommendations.